AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03856658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Infusion Pump
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
Study NCT03856658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparinized Saline
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
Study NCT00819260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel
Description: harmonic scalpel used to reduce breast on this side
Study NCT00819260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery
Description: Electrocautery used to reduce breast on this side
Study NCT03696615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tabata Kettlebell Swing Workout
Description: See description of experimental arm.
Study NCT03696615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: see description of control arm
Study NCT00887250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: 50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
Study NCT00887250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: losartan
Description: 50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
Study NCT00887250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to Losartan
Study NCT03394430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients in Group A receive intranasal normal saline before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
Study NCT03394430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients in Group B receive intranasal 0.25mg/kg midazolam before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
Study NCT03394430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in Group C receive intranasal 1μg/kg dexmedetomidine before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
Study NCT02672709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Study NCT02877836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging (fMRI)
Description: To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
Study NCT02271074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care CD4 testing
Description: Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
Study NCT02271074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Facilitation
Description: The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
Study NCT02271074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transport support
Description: The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
Study NCT02569554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
Study NCT02569554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
Study NCT02767401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenting or balloon expansion
Description: all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
Study NCT02767401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
Study NCT05334537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of >37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
Study NCT05334537 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil (odorless baby oil- jojoba and almond oil)
Description: Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of >37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
Study NCT03357952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).
Study NCT03357952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63723283
Description: Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.
Study NCT01297413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic adult mesenchymal bone marrow stem cells
Description: Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
Study NCT03445923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time lapse monitoring (KID Score)
Description: The unique information that is obtainable from taking Pictures each 10 minutes throughout the development of the embryos will be used in the form of a special score (KID score). The score is comprised out of several key developmental parameters.
Study NCT02463825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide 2 mg per day
Study NCT02463825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide 4 mg per day
Study NCT02463825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Lactose tablet)
Study NCT01956500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Instaflex
Description: The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
Study NCT01956500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will contain magnesium stearate, an inert substance.
Study NCT03080688 — intervention group
Intervention type: DEVICE
Intervention: Prizma Oxygen Saturation Measurement
Description: A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1).
Study NCT00105950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Tyrosine kinase inhibitor administered daily at 1500 mg/kg
Study NCT04086654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: International Trauma Interview (ITI) for ICD-11 PTSD and Complex PTSD - German version
Description: The ITI consists of 18 items and for each symptom, standardized questions as well as probes are presented. A trained professional rates both symptom frequency and intensity, which are converted into an overall index of symptom severity. A diagnosis of PTSD/CPTSD is established by applying the ICD-11 diagnostic rules. It takes approximately 30-60 minutes to administer.
Study NCT04169386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: AK102 single dose administered subcutaneously
Study NCT04169386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose administered subcutaneously
Study NCT02027701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Study NCT04024774 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological samples
Description: blood samples, urine samples, tissue samples
Study NCT04024774 — intervention group
Intervention type: GENETIC
Intervention: Genetic test
Description: anamnesis and NGS sequencing
Study NCT00286078 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Precision
Description: Implantable neurostimulator
Study NCT00286078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision
Description: Implantable neurostimulator
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Description: One 90 mg tablet once daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Description: Two 60 mg tablets once daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: One tablet three times daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Etoricoxib 120 mg
Description: Two tablets once daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo for Etoricoxib 120 mg
Description: Two tablets once daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Etoricoxib 120 mg
Description: Two tablets once daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Etoricoxib 90 mg
Description: One tablet once daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo for Etoricoxib 90 mg
Description: One tablet once daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Etoricoxib 90 mg
Description: One tablet once daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Ibuprofen
Description: One tablet three times daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Ibuprofen
Description: One tablet three times daily
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg as needed
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5 mg as needed
Study NCT00820027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5 mg as needed
Study NCT02796820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granule is continuously taken three times per day, 20g per time.
Study NCT02051270 — intervention group
Intervention type: OTHER
Intervention: Descriptive study
Description: More than 65 years old elders
Study NCT02982187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA
Description: It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
Study NCT02982187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo DISKUS
Description: It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
Study NCT02982187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TURBUHALER
Description: It is a placebo dry powder inhaler containing lactose monohydrate.
Study NCT02982187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo HANDIHALER
Description: Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
Study NCT02982187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PQ1
Description: Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
Study NCT02982187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PQ2
Description: Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
Study NCT02982187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PQ3
Description: Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
Study NCT02982187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PQ4
Description: Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
Study NCT03629951 — intervention group
Intervention type: DRUG
Intervention: Oral Antipsychotics (OAP)
Description: This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
Study NCT04392453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic therapy
Description: The treatment with the robot Icone will include 30 sessions, each session lasting 45 minutes, with a frequency from three to five times a week. The treatment will be provided in the patient's room. Patients will execute upper limb movement involving elbow flexion-extension, shoulder protraction-retraction, internal-external rotation, flexion-extension, and abduction-adduction. Visual and auditory feedback will be provided during the tasks. The exercises will train both motor and cognitive functions.
Study NCT04227548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: needle electromyography
Description: Direct muscle stimulation was performed to deltoid and tibialis anterior muscles with a monopolar needle electrode. Recording was made with a concentric needle electrode.
Study NCT02053987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation in the home.
Study NCT03493841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
Study NCT04201756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: ①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)
Study NCT01324323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
Study NCT01324323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg oral once daily on Days 4-8
Study NCT00509587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given orally
Study NCT00509587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00509587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01869257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triclosan coated suture
Description: The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
Study NCT01869257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regular suture
Description: The control arm will have the abdominal wound sutured with a regular non-coated suture